购物车
- 全部删除
- 您的购物车当前为空
BCMA/TNFRSF17 Protein, Human, Recombinant, AF488-Labeled is expressed in HEK293 Cells. The accession number is Q02223-1.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
25 μg | ¥ 3,430 | 期货 | |
100 μg | ¥ 10,900 | 期货 |
生物活性 | Activity testing is in progress. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first. |
产品描述 | BCMA/TNFRSF17 Protein, Human, Recombinant, AF488-Labeled is expressed in HEK293 Cells. The accession number is Q02223-1. |
种属 | Human |
表达系统 | HEK293 Cells |
标签 | C-His |
蛋白编号 | Q02223-1 |
别名 | TNFRSF13A,CD269,BCMA,BCM |
蛋白构建 | A DNA sequence encoding the extracellular domain (Met1-Ala54) of human TNFRSF17 (NP_001183.2) was expressed with a C-terminal polyhistidine tag. The protein is site-specifically conjugated with AF 488 (Excitation Max.= 495 nm, Emission Max.= 519 nm). |
蛋白纯度 | ≥ 90% as determined by SDS-PAGE. |
分子量 | 11.8 kDa (predicted) |
内毒素 | < 1.0 EU per μg protein as determined by the LAL method. |
缓冲液 | This product is Lyophilized from sterile PBS, pH 7.4, with 5 %-8 % trehalose. Please contact us for any concerns or special requirements. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
复溶方法 | Please refer to the lot-specific COA. |
存储 | Twelve months from date of receipt at -20℃ to -70℃ in lyophilized form and 3 months at -70℃ under sterile conditions after reconstitution. Protect from prolonged exposure to light and avoid repeated freeze-thaw cycles. |
运输方式 | In general, Lyophilized powders are shipping with blue ice. |
研究背景 | Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo. |